Literature DB >> 32601160

Prolonged Exposure to β-Lactam Antibiotics Reestablishes Susceptibility of Daptomycin-Nonsusceptible Staphylococcus aureus to Daptomycin.

Rachel E Jenson1, Sarah L Baines2, Benjamin P Howden2, Nagendra N Mishra3,4, Sabrina Farah3,4, Cassandra Lew1, Andrew D Berti1, Sanjay K Shukla5, Arnold S Bayer3,4, Warren E Rose6.   

Abstract

Daptomycin-nonsusceptible (DAP-NS) Staphylococcus aureus often exhibits gain-in-function mutations in the mprF gene (involved in positive surface charge maintenance). Standard β-lactams, although relatively inactive against methicillin-resistant S. aureus (MRSA), may prevent the emergence of mprF mutations and DAP-NS. We determined if β-lactams might also impact DAP-NS isolates already possessing an mprF mutation to revert them to DAP-susceptible (DAP-S) phenotypes and, if so, whether this is associated with specific penicillin-binding protein (PBP) targeting. This study included 25 DAP-S/DAP-NS isogenic, clinically derived MRSA bloodstream isolates. MICs were performed for DAP, nafcillin (NAF; PBP-promiscuous), cloxacillin (LOX; PBP-1), ceftriaxone (CRO; PBP-2), and cefoxitin (FOX; PBP-4). Three DAP-NS isolates were selected for a 28-day serial passage in subinhibitory β-lactams. DAP MICs and time-kill assays, host defense peptide (LL-37) susceptibilities, and whole-genome sequencing were performed to associate genetic changes with key phenotypic profiles. Pronounced decreases in baseline MICs were observed for NAF and LOX (but not for CRO or FOX) among DAP-NS versus DAP-S isolates ("seesaw" effect). Prolonged (28-d) β-lactam passage of three DAP-NS isolates significantly reduced DAP MICs. LOX was most impactful (∼16-fold decrease in DAP MIC; 2 to 0.125 mg/liter). In these DAP-NS isolates with preexisting mprF polymorphisms, accumulation of additional mprF mutations occurred with prolonged LOX exposures. This was associated with enhanced LL-37 killing activity and reduced surface charge (both mprF-dependent phenotypes). β-lactams that either promiscuously or specifically target PBP-1 have significant DAP "resensitizing" effects against DAP-NS S. aureus strains. This may relate to the acquisition of multiple mprF single nucleotide polymorphism (SNPs), which, in turn, affect cell envelope function and metabolism.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  cationic peptide; methicillin-resistant Staphylococcus aureus; mprF; penicillin-binding protein

Mesh:

Substances:

Year:  2020        PMID: 32601160      PMCID: PMC7449200          DOI: 10.1128/AAC.00890-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Sung-Han Kim; Kye-Hyung Kim; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

2.  Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.

Authors:  Andrew D Berti; Justine E Wergin; Gary G Girdaukas; Scott J Hetzel; George Sakoulas; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

3.  Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics.

Authors:  Andrew D Berti; Sarah L Baines; Benjamin P Howden; George Sakoulas; Victor Nizet; Richard A Proctor; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

Review 4.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

5.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

6.  Impact of Multiple Single-Nucleotide Polymorphisms Within mprF on Daptomycin Resistance in Staphylococcus aureus.

Authors:  Soo-Jin Yang; Nagendra N Mishra; Kyoung-Mi Kang; Gi-Yong Lee; Jong-Hwan Park; Arnold S Bayer
Journal:  Microb Drug Resist       Date:  2018-01-30       Impact factor: 3.431

7.  Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Hui-min Neoh; Mitsutaka Shoji; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

8.  Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Authors:  Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

9.  Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides.

Authors:  Arnold S Bayer; Nagendra N Mishra; George Sakoulas; Poochit Nonejuie; Cynthia C Nast; Joseph Pogliano; Kuan-Tsen Chen; Steven N Ellison; Michael R Yeaman; Soo-Jin Yang
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

10.  Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.

Authors:  Benjamin P Howden; Christopher R E McEvoy; David L Allen; Kyra Chua; Wei Gao; Paul F Harrison; Jan Bell; Geoffrey Coombs; Vicki Bennett-Wood; Jessica L Porter; Roy Robins-Browne; John K Davies; Torsten Seemann; Timothy P Stinear
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

View more
  5 in total

1.  Phenotypic and genetic changes associated with the seesaw effect in MRSA strain N315 in a bioreactor model.

Authors:  Smruti Mishra; Erica Lasek-Nesselquist; Anarv Mathur; Zhuo Ma; Kanpong Boonthaworn; Nicholas O'Donnell; Haixin Sui; Janice D Pata; Kathleen A McDonough; Pradeepa Jayachandran; Meenakshi Malik
Journal:  J Glob Antimicrob Resist       Date:  2022-01-24       Impact factor: 4.349

2.  The Role of mprF Mutations in Seesaw Effect of Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Isolates.

Authors:  Shengnan Jiang; Hemu Zhuang; Feiteng Zhu; Xiang Wei; Junxiong Zhang; Lu Sun; Shujuan Ji; Haiping Wang; Dandan Wu; Feng Zhao; Rushuang Yan; Yunsong Yu; Yan Chen
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

3.  Proteomic Correlates of Enhanced Daptomycin Activity following β-Lactam Preconditioning in Daptomycin-Resistant, Methicillin-Resistant Staphylococcus aureus.

Authors:  Cassandra Lew; Molly Pellitteri Hahn; Cameron Scarlett; Aaron Rottier; Andrew D Berti; Richard A Proctor; Arnold S Bayer; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.938

4.  Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics.

Authors:  Nagendra N Mishra; Cassandra Lew; Wessam Abdelhady; Christian K Lapitan; Richard A Proctor; Warren E Rose; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

5.  Cell Membrane Adaptations Mediate β-Lactam-Induced Resensitization of Daptomycin-Resistant (DAP-R) Staphylococcus aureus In Vitro.

Authors:  Nagendra N Mishra; Arnold S Bayer; Sarah L Baines; Ashleigh S Hayes; Benjamin P Howden; Christian K Lapitan; Cassandra Lew; Warren E Rose
Journal:  Microorganisms       Date:  2021-05-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.